Key Takeaways
- SBRT is high-precision external-beam radiation for selected targets outside the brain. A short schedule does not make it a minor treatment: each fraction carries a comparatively high dose.
- Eligibility depends on the target's size, location, motion, nearby organs, prior radiation and the role of SBRT in the patient's whole cancer plan—not on owning a named machine.
- Simulation, immobilisation, motion management, image guidance and physics checks are part of treatment. The first radiation fraction should not be confused with the first planning visit.
- A central lung lesion beside the main airways, or a target close to bowel, stomach, spinal cord or another sensitive structure, may need more fractions, a different dose or another treatment.
- Post-SBRT imaging can show treatment-related change. Follow-up should be reviewed by a team familiar with the treated field rather than declaring recurrence from one scan alone.
Content
SBRT—also called stereotactic ablative body radiotherapy, or SABR—is a form of external-beam radiation that uses precise positioning and focused dose delivery for tumours in the body outside the brain.[1] In Chinese terminology standards, stereotactic radiotherapy uses dedicated positioning and localisation to focus a small field; SBRT is the extracranial form.[2] Treatment in the brain is generally called stereotactic radiosurgery (SRS) or fractionated stereotactic radiotherapy, even though no surgical incision is made.
The attraction is easy to understand: selected patients may complete treatment in a few fractions rather than several weeks. The important qualification is that fewer visits usually mean a higher dose per fraction and tighter dependence on geometric accuracy. SBRT is not simply conventional radiation delivered faster.
The first decision is whether SBRT belongs in this cancer plan
Ask the radiation oncologist to name the clinical role:
- definitive local treatment for an early, localised tumour;
- local treatment when surgery is not suitable or is declined;
- control of a limited metastatic or recurrent site as part of a broader plan;
- consolidation after systemic treatment;
- re-irradiation of a previously treated area; or
- symptom control when a stereotactic course offers a specific advantage.
That purpose affects the dose, number of fractions, expected benefit and acceptable risk. A technically treatable spot is not necessarily the disease that most urgently needs treatment. Active disease elsewhere, an uncertain diagnosis or a systemic-treatment priority may change the sequence.
NCI describes SBRT as an option for small, isolated tumours outside the brain and spinal cord, often in lung or liver, including some patients who cannot undergo surgery because of health, age or tumour location.[3] This is not a rule that every small lesion should receive SBRT. Where surgery, ablation, conventional radiation, systemic therapy or observation is reasonable, ask the multidisciplinary team to compare outcomes, tissue diagnosis, recovery, side effects and what each option leaves available later.
Location matters as much as size
A plan cannot be judged by the prescription alone. The same dose and fraction count may be acceptable for a peripheral target and unsafe beside a major airway, oesophagus, bowel loop, stomach, duodenum, spinal cord, brachial plexus, chest wall, kidney or liver remnant.
For lung tumours, “central” and “ultracentral” are risk descriptions, not marketing categories. NCI's professional summary notes that three-fraction SBRT is contraindicated for central early-stage non-small-cell lung cancer based on earlier safety data and that more protracted, risk-adapted schedules have been studied.[4] Patients should not apply that lung-specific example to another organ, but it demonstrates why “five treatments versus three” cannot be compared without anatomy and organ dose constraints.
Before accepting the plan, request a plain-language answer to four questions:
- What is the target, and how certain is its boundary?
- Which nearby organ limits the dose?
- How does movement change the target position?
- What would make the team use more fractions, lower the dose or choose another method?
Previous radiation is a separate high-risk issue. Supply the earlier DICOM-RT plan, dose, structure set and treatment summary whenever possible. A sentence saying “radiation to the chest” does not show cumulative dose to the spinal cord, airway, lung or oesophagus.
Simulation is a rehearsal with measurements
The planning appointment usually establishes a position that can be reproduced at every fraction. Devices may include a shaped cushion, vacuum bag, abdominal compression, arm support or other immobilisation. The team obtains a planning CT and may fuse diagnostic CT, MRI or PET information when appropriate.
Targets in lung, liver, pancreas and upper abdomen can move with breathing. Depending on the case and equipment, the solution may be four-dimensional CT, breath-hold, respiratory gating, abdominal compression or real-time tracking. Some workflows use implanted fiducial markers; others do not. A marker is not automatically necessary, and placing one has its own procedure risks.
Ask the patient to rehearse the required breathing instruction before travel if possible. Someone unable to lie flat, keep the arms up, tolerate immobilisation or reproduce breath-hold may need a different motion strategy. Sedation is not a casual solution because breathing pattern and safe transport also matter.
After simulation, the radiation oncologist defines target volumes and organs at risk; dosimetrists and medical physicists develop and check the plan. This interval may take days. Do not book a return flight assuming radiation will begin immediately after the CT.
Precision is a process, not a machine brand
SBRT can be delivered on different capable platforms. A robotic arm, conventional linear accelerator, ring gantry or brand name does not replace the following questions:
- Is the team trained and credentialed for this disease site and technique?
- How is the machine's small-field accuracy checked?
- Is patient-specific plan verification performed?
- What imaging is acquired before each fraction, and is position corrected online?
- How is motion monitored during delivery?
- Who decides whether anatomy has changed too much to treat that day?
China's WS 582—2017 standard defines quality-control tests for X- and gamma-ray stereotactic systems and their localisation and radiation-field accuracy.[5] The national radiotherapy protection standard also requires a quality-assurance programme covering immobilisation, localisation, plan design, dose delivery, verification, identity and site checks, calibration, record keeping and correction of deviations.[6] ASTRO's safety white paper similarly describes SRS/SBRT as a resource-intensive, team-based technique requiring trained personnel and a comprehensive quality-assurance programme.[7]
On treatment day, staff reproduce the planned position and acquire image guidance—often cone-beam CT or another volumetric/planar image—to align the target or surrogates. They may pause or re-image if the patient moves or treatment is long. Asking why a fraction was delayed for re-planning or equipment quality assurance is appropriate; rescheduling can be the safer decision.
A short course can have early and late effects
Side effects follow the irradiated organ and dose. Lung SBRT may cause fatigue, cough, chest-wall discomfort, rib injury or radiation pneumonitis; liver treatment may affect nearby stomach, bowel or liver function; spine treatment requires particular attention to cord and vertebral risks; prostate schedules have urinary, bowel and sexual effects. This is not an exhaustive list, and risks differ markedly by target.
Ask the team to distinguish:
- common short-term effects and home care;
- symptoms that require a same-day call;
- urgent symptoms such as severe breathlessness, chest pain, new weakness, loss of bladder or bowel control, bleeding or rapid deterioration;
- possible late effects and how long they will be monitored.
SBRT does not make the patient radioactive. The beams come from outside the body and stop when the machine is off.[3]
Follow-up imaging needs the treatment map
The first scan is not a simple pass/fail test. Inflammation, scarring, temporary enlargement or changing contrast uptake can occur in the treated region. The timing and appearance depend on the organ and modality. Conversely, not every new opacity is harmless radiation change.
Arrange follow-up before leaving China: date and imaging type, who compares it with the simulation and prior diagnostic studies, when a multidisciplinary review is triggered, and how suspected recurrence would be confirmed. If care returns home, provide the receiving team with the treatment summary and, when available, the plan and dose data. One scan interpreted without the treatment field can lead to premature reassurance or premature declaration of progression.
The completion record should include diagnosis and intent, treated site, simulation date, technique, prescription, delivered dose, dose per fraction, number and dates of fractions, interruptions, motion-management method, implanted markers, relevant toxicity and the follow-up plan.
Compare the whole episode, not a per-fraction price
An estimate should separate specialist review, repeat imaging or pathology, simulation, contrast, immobilisation, fiducial placement if needed, planning, physics quality assurance, image guidance, every fraction, on-treatment review and follow-up. Ask what happens if the target is unsuitable after simulation, if replanning is required, or if a fraction is cancelled because anatomy or equipment checks fail.
Travel dates should allow for planning and clinical review after the last fraction. Site-specific complications may not appear before the patient boards a plane; a named home-country radiation oncologist and an emergency plan remain necessary.
Medical disclaimer: This guide provides general education and cannot determine SBRT eligibility, dose or fractionation. Those decisions require review by a radiation oncologist and qualified physics team using the patient's complete pathology, imaging, prior treatment and organ-at-risk constraints. Severe or rapidly worsening symptoms require urgent local assessment.
Related Hospitals
List only centres whose stereotactic radiotherapy licence, disease-site experience, medical-physics support, image guidance and complication pathway have been verified.
Related Treatments
Do not link SBRT as a generic upgrade. Relate it only to a defined tumour site and clinical indication after specialist review.
Related Guides
- Radiation therapy in China
- Transferring DICOM and prior radiotherapy plans
- Multidisciplinary cancer care
- Follow-up after treatment abroad
FAQ
Is SBRT the same as radiosurgery?
Both use stereotactic localisation and focused external radiation, but SBRT usually refers to targets outside the brain. SRS is commonly used for intracranial treatment. Neither requires a surgical incision.[1][2]
Why can two patients with similar-sized tumours receive different numbers of fractions?
Location, motion, nearby sensitive organs, prior radiation and treatment intent can all change the safe schedule. A risk-adapted course may use more fractions to respect organ limits; fewer visits are not automatically better.[4]
Do all lung or liver targets need implanted fiducial markers?
No. The need depends on target visibility, motion-management method and treatment platform. Ask how the team will localise and track the target and what risks a marker-placement procedure would add.
Can one scan after SBRT prove that treatment failed?
Usually not by itself. Treatment-related inflammation and scarring can alter size or appearance. The team should compare serial imaging with the treated field, clinical status and expected timing, and investigate when recurrence remains suspected.
What SBRT records should I take home?
Obtain the treatment summary with site, intent, technique, total and per-fraction dose, dates, motion method, toxicity and follow-up. If future radiation is possible, also ask for DICOM-RT plan, dose and structure files.
Sources
- US National Cancer Institute — Definition of SBRT
- National Health Commission of China — WS/T 831—2024 Basic Terminology of Medical Radiation Protection
- US National Cancer Institute — External Beam Radiation Therapy for Cancer
- US National Cancer Institute — Non-Small Cell Lung Cancer Treatment (PDQ), SBRT Section
- National Health Commission of China — WS 582—2017 Quality Control Testing for X- and Gamma-Ray Stereotactic Radiotherapy Systems
- National Health Commission of China — GBZ 121—2020 Requirements for Radiotherapy Protection and Quality Assurance
- American Society for Radiation Oncology — SRS/SBRT Quality and Safety White Paper Update
Hero Image Review
- Decision: Approved and retained as hero-reviewed.png.
- Why: The image clearly shows a body CT cross-section, a small defined target and converging beam paths while a clinician explains the concept. It is recognisably related to SBRT and contains no patient identifiers, brand claims or graphic procedure details.
- Editorial note: The beam display is intentionally simplified and must not be presented as a real patient plan or an exact depiction of dose distribution.